We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+30.09%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$238M
AUM Growth
-$14.5M
Cap. Flow
-$47.8M
Cap. Flow %
-20.06%
Top 10 Hldgs %
75.28%
Holding
38
New
2
Increased
10
Reduced
3
Closed
13

Top Buys

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$8.18M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$5.51M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$5.19M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.45M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$3.84M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$22M
2
DYAX
DYAX CORPORATION
DYAX
+$14.3M
3
RLYP
RELYPSA INC COM
RLYP
+$14.2M
4
MDCO
Medicines Co
MDCO
+$5.69M
5
STML
Stemline Therapeutics, Inc.
STML
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 58.12%
2 Technology 6.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
26
Neurogene
NGNE
$656M
– –
-5,000
Closed -$1.41M
ALIM
27
DELISTED
Alimera Sciences
ALIM
– –
-112,211
Closed -$3.72M
MTEM
28
CALL
DELISTED
Molecular Templates, Inc.
MTEM
– –
-1,278
Closed -$858K
ALBO
29
DELISTED
Albireo Pharma Inc
ALBO
– –
-110,566
Closed -$1.46M
ATRS
30
DELISTED
Antares Pharma, Inc.
ATRS
– –
-1,018,627
Closed -$1.73M
GWPH
31
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-103,800
Closed -$9.48M
STML
32
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-475,200
Closed -$4.2M
MDCO
33
DELISTED
Medicines Co
MDCO
– –
-150,000
Closed -$5.69M
WINT
34
DELISTED
Windtree Therapeutics Inc
WINT
– –
-180,752
Closed -$759K
RLYP
35
DELISTED
RELYPSA INC COM
RLYP
– –
-769,047
Closed -$14.2M
DYAX
36
DELISTED
DYAX CORPORATION
DYAX
– –
-750,000
Closed -$14.3M
OSIR
37
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
– –
-75,000
Closed -$1.39M
DSCI
38
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-101,235
Closed -$477K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2015 Portfolio in Review

As of Q4 2015, Great Point Partners held 38 positions worth $238M, down 5.7% from $253M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Great Point Partners withdrew a net $47.8M in Q4 2015, closing 13 positions and reducing 3 holdings. Its most notable exit was DYAX CORPORATION, an estimated $14.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 54% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners added an estimated $8.18M to Tetraphase Pharmaceuticals, Inc..

  • Great Point Partners added most to Tetraphase Pharmaceuticals, Inc. in Q4 2015, an estimated $8.18M increase.
  • Great Point Partners's biggest Q4 2015 reduction was Five Prime Therapeutics, Inc., cutting an estimated $22M.
  • Great Point Partners fully exited DYAX CORPORATION in Q4 2015, selling an estimated $14.3M.
  • Great Point Partners's ten largest holdings make up 75% of its $238M portfolio in Q4 2015.
  • Great Point Partners opened 2 new positions and closed 13 in Q4 2015.
  • Great Point Partners's portfolio value fell 5.7% quarter-over-quarter to $238M.

Based on Great Point Partners's 13F filing for Q4 2015, filed 16 Feb 2016.